Metabolon has introduced new liver fibrosis and kidney function discovery panels for revealing disease mechanisms and enabling research.
The new panels are part of the Metabolon Discover portfolio of metabolomics services and are intended to evaluate several metabolites across diverse biological pathways that are associated with kidney disease and liver fibrosis.
Leveraging new visualisation tools, the panels will allow researchers to compare results across different data sets for detecting and understanding statistically significant change impacts in metabolite abundance.
The liver fibrosis discovery panel helps analyse 105 metabolites across multiple biological processes.
Using this panel, researchers will be able to detect the suitable markers connected to liver fibrosis and address key challenges regarding drug discovery and testing, personalised medicine and mechanistic insights.
The kidney function discovery panel has been designed to analyse 84 metabolites associated with biochemical processes that affect kidney function. It will help researchers in differentiating the diverse spectrum of kidney disease.
Metabolon chief scientific officer Rangaprasad Sarangarajan said: “Our new Liver Fibrosis and Kidney Function Discovery Panels seek to reveal fundamental metabolic changes, thereby facilitating our understanding of the underlying mechanisms of these diseases.
“Metabolon is committed to providing insights that can ultimately lead to the creation of tools improving patient outcomes through earlier detection, better monitoring and improved treatments.”
Both chronic liver and kidney diseases can be treated if detected early, but more research is required to understand the underlying causes of these ailments.
